Literature DB >> 24093319

Endovascular abdominal aneurysm repair and impact of systematic preoperative embolization of collateral arteries: endoleak analysis and long-term follow-up.

Mario Alerci1, Alessia Giamboni, Rolf Wyttenbach, Alessandra Pia Porretta, Francesco Antonucci, Marcel Bogen, Marco Toderi, Adriano Guerra, Fabio Sartori, Paolo Tutta, Luigi Inglese, Costanzo Limoni, Augusto Gallino, Ludwig K Von Segesser.   

Abstract

PURPOSE: To report our results of endovascular aneurysm repair (EVAR) over a 10-year period using systematic preoperative collateral artery embolization.
METHODS: From 1999 until 2009, 124 patients (117 men; mean age 70.8 years) with abdominal aortic aneurysm (AAA) underwent embolization of patent lumbar and/or inferior mesenteric arteries prior to elective EVAR procedures. Embolization was systematically attempted and, whenever possible, performed using microcoils and a coaxial technique. Follow-up included computed tomography and/or magnetic resonance imaging and abdominal radiography.
RESULTS: The technical success for EVAR was 96% (119/124), with 4 patients dying within 30 days (3.2% perioperative mortality) and 1 type III endoleak accounting for the failures. Collateral arteries were occluded spontaneously or by embolization in 60 (48%) of 124 patients. The endoleak rate was 50.9% (74 in 61 patients), most of which were type II (19%). Over a mean clinical follow-up of 60.5±34.1 months (range 1-144), aneurysm sac dimensions decreased in 66 patients, increased in 19 patients, and were stable in 35. The endoleak rate was significantly higher in the patients with increasing sac diameter (p<0.001). Among the patients with patent collateral arteries, 38/64 (59.3%) developed 46 leaks, while 28 leaks appeared in 23 (41%) of 56 patients with collateral artery occlusion (p=0.069). The type II endoleak rate significantly differed between these two groups (47.8% vs. 3.6%, p<0.001).
CONCLUSION: Preoperative collateral embolization seems to be a valid method of reducing the incidence of type II endoleak, improving the long-term outcome.

Entities:  

Mesh:

Year:  2013        PMID: 24093319     DOI: 10.1583/12-4188MR.1

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  6 in total

1.  Abdominal Aortic Aneurysm Type II Endoleaks.

Authors:  Mohamed S Kuziez; Luis A Sanchez; Mohamed A Zayed
Journal:  J Cardiovasc Dis Diagn       Date:  2016-08-20

2.  Effectiveness of Embolization of Inferior Mesenteric Artery to Prevent Type II Endoleak Following Endovascular Aneurysm Repair: A Review of the Literature.

Authors:  Makoto Samura; Noriyasu Morikage; Takahiro Mizoguchi; Yuriko Takeuchi; Takashi Nagase; Takasuke Harada; Kotaro Suehiro; Kimikazu Hamano
Journal:  Ann Vasc Dis       Date:  2018-09-25

3.  Predictive Factor of the Possibility for Aortic Side Branches Coil Embolization during Endovascular Abdominal Aortic Aneurysm Repair.

Authors:  Atsushi Aoki; Kazuto Maruta; Norifumi Hosaka; Tomoaki Masuda; Tadashi Omoto; Yui Horikawa
Journal:  Ann Vasc Dis       Date:  2020-09-25

4.  Systematic review and network meta-analysis of pre-emptive embolization of the aneurysm sac side branches and aneurysm sac coil embolization to improve the outcomes of endovascular aneurysm repair.

Authors:  Ye Wu; Jianhan Yin; Zhang Hongpeng; Guo Wei
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 5.  Techniques and future perspectives for the prevention and treatment of endoleaks after endovascular repair of abdominal aortic aneurysms.

Authors:  Gianluigi Orgera; Marcello Andrea Tipaldi; Florindo Laurino; Pierleone Lucatelli; Alberto Rebonato; Ioannis Paraskevopoulos; Michele Rossi; Miltiadis Krokidis
Journal:  Insights Imaging       Date:  2019-09-23

6.  Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study.

Authors:  Shigeo Ichihashi; Mitsuyoshi Takahara; Naoki Fujimura; Satoru Nagatomi; Shinichi Iwakoshi; Francesco Bolstad; Kimihiko Kichikawa
Journal:  BMJ Open       Date:  2020-02-16       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.